Below are the earnings highlights for Ligand Pharmaceuticals Inc (LGND):
Earnings: -$7.17 million in Q3 vs. -$10.27 million in the same period last year. EPS: -$0.39 in Q3 vs. -$0.59 in the same period last year. Excluding items, Ligand Pharmaceuticals Inc reported adjusted earnings of $35.32 million or $1.84 per share for the period.
Analysts projected $1.35 per share Revenue: $51.81 million in Q3 vs. $32.87 million in the same period last year.
-Guidance:Full year EPS guidance: $5.50 - $5.70Full year revenue guidance: $160 - $165 Mln
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.